In this article, we aim to explain how monoclonal antibodies can help in the fight against the COVID-19 pandemic. While there are still unknowns about these drugs –such as their real-life efficacy and long-term effects, amongst others –antibodies nonetheless have the potential to effectively target several stages of the disease with evident benefits at a patient level (by alleviating symptoms and preventing progression to severe disease) and at a systemic level (by reducing the strain on the overburdened health systems worldwide). The next months will be crucial to understand how antibodies will be accepted by the market and to assess how they will be used, however, recent government agreements show that countries best act soon to ensure supply, as access may be mainly dictated by country-level agreements.